Femulen

Quick links to important sections

Femulen

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Femulen

Quick Facts

Property Description
Active ingredient Etynodiol diacetate
Form Tablet (Oral)
Pharmacological class Progestin (Synthetic Progestogen)
Common use Prevention of pregnancy (Contraception)
Origin Synthetic steroid derivative
Prescription Status Prescription-only

What Type of Contraceptive is Femulen?

Femulen is classified as a Progestogen-Only Pill (POP), a specialized prescription oral medication used for the prevention of pregnancy. This medicine is a single-ingredient product containing only a synthetic form of the hormone progesterone, which distinguishes it from combined oral contraceptives.

This formulation is often referred to as the "mini-pill" and is administered as an oral tablet. It belongs to the hormonal contraceptive class, specifically the pharmacological category of progestins. This singular hormonal composition makes it a contraceptive option for women who must avoid estrogens due to specific medical or physiological considerations.

Composition and Origin: The Role of Etynodiol Diacetate

The pharmacological activity of Femulen is attributed to its active ingredient, etynodiol diacetate, which is a synthetic progestogen. Etynodiol diacetate is chemically classified as a synthetic steroid derivative originating from the 19-nortestosterone group.

This compound functions as a prodrug; upon metabolism, it is converted into the primary active metabolite, norethisterone. This chemical process enables the compound to function as a progesterone receptor agonist. This singular, non-estrogenic composition is central to the medication's identity and mechanism of action.

Understanding the General Purpose of Femulen

The fundamental purpose of Femulen is to provide a method of hormonal contraception by influencing the reproductive cycle through multiple effects. These physiological actions primarily involve the thickening of the cervical mucus, which creates a physical barrier that restricts sperm movement into the uterus.

Evidence indicates that progestogen-only pills, such as Femulen, are effective through the concurrent alteration of the endometrial lining, which reduces the likelihood of a fertilized egg implanting successfully. This mechanism supports the medication’s primary role in the prevention of pregnancy.

Regulatory References

  1. Progestins - NIH/NCBI

What side effects are possible with Femulen?

Possible side effects and safety information

This section outlines the officially documented adverse reactions and safety characteristics of Femulen (etynodiol diacetate) as classified in government regulatory sources, focusing on the Progestogen-Only Pill (POP) safety profile.

Frequency and System-Organ Classes

The most frequently documented safety characteristic is the effect on the Reproductive System and Breast Disorders, which results in changes to the menstrual cycle. This can include irregular bleeding, spotting (breakthrough bleeding), or the absence of periods (amenorrhea), effects often noted during the first few months of treatment.

Adverse effects classified as common in official safety documents occur across other system-organ classes, including Nervous System Disorders (e.g., headache, dizziness), Gastrointestinal Disorders (e.g., nausea), and Skin and Subcutaneous Tissue Disorders (e.g., acne, melasma, which is associated with long-term exposure). Other common effects include breast tenderness, weight gain, and changes in appetite.

Serious Adverse Reactions and Restrictions

Regulatory documents identify the potential for Thromboembolic Events (blood clots) and Hepatic Abnormalities (such as liver tumors) as serious, label-documented safety concerns. The medicine is formally restricted or contraindicated in individuals with high risk for arterial or venous thrombotic diseases, severe liver disease, or unexplained vaginal bleeding.

Population-specific safety considerations state that the risk of serious cardiovascular side effects is substantially increased in women who smoke and are over 35 years old. Official safety guidance indicates that this medicine is suitable for use during the postpartum period, including when breastfeeding.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory classification for an overdose of Femulen (etynodiol diacetate) indicates that the product is of generally low toxicity, and severe or life-threatening outcomes are not typically expected. However, immediate action is required for any known or suspected overdose.

Required Emergency Actions

In the event of an overdose, it is officially mandated to seek immediate medical attention or contact emergency services and Poison Control. Medical professionals must be contacted to determine the appropriate course of action, even if no symptoms are present.

Documented Clinical Manifestations

The clinical signs of overdose documented in official prescribing information are typically mild and transient. These include gastrointestinal disturbances such as nausea and vomiting. A common manifestation observed in females following an overdose is withdrawal bleeding, which presents as irregular uterine bleeding.

Management and Treatment

Due to the absence of a known specific antidote for etynodiol diacetate, the required management approach is strictly symptomatic and supportive treatment. This typically involves hospital monitoring, including the observation of vital signs. In cases of significant acute ingestion, medical procedures such as the administration of activated charcoal may be considered by healthcare providers.

Population Considerations

Specific regulatory notes indicate that overdose in children or young girls is associated with mild, short-term symptoms, and no long-term adverse effects are expected.

Therapeutic Uses of Femulen

Main Uses and Benefits of Femulen

Femulen's therapeutic function is entirely prophylactic, focusing on preventing conception rather than treating existing symptoms or conditions. Its application centers on providing supportive contraceptive management. This method is generally used for long-term family planning and as a method of fertility control.

Femulen is considered relevant in contexts where systemic effects of estrogen must be avoided due to existing medical conditions, and it is also often applied in the clinical setting of the postpartum period for breastfeeding women. The medication is commonly used for the prevention of pregnancy in women of childbearing age, particularly those who require an estrogen-free alternative. This specialized formulation may help patients access ongoing contraceptive management.

“This therapeutic role supports patients whose health conditions may require them to avoid estrogenic products.”

Quick Fact: Contraceptive Focus

Property Description
Main Indication Prevention of pregnancy
Clinical Context Need for estrogen avoidance
Supportive Benefit Contraceptive support

Eligibility and Restrictions for Use

Who can and cannot use Femulen?

Eligibility to use the Progestogen-Only Pill (POP) Femulen is defined by regulatory guidelines through specific absolute contraindications and conditions requiring special precautionary use. This medicine is indicated for women of childbearing age who require an estrogen-free contraceptive option.

Category Regulatory Status
Absolute Contraindications Use is prohibited if pregnancy is suspected or diagnosed. Use is also prohibited in patients with a history of breast cancer or other hormone-sensitive cancers, malignant or benign liver tumours, or active liver disease (e.g., jaundice).
Conditional Use Patients with pre-existing conditions like diabetes, epilepsy, migraine, high blood pressure, or heart and kidney problems require closer monitoring during use.
Pregnancy/Lactation Contraindicated during pregnancy. Permitted for use in breastfeeding women and may be started from day 21 after childbirth.

Official documents also stipulate that use is prohibited in the presence of undiagnosed abnormal vaginal bleeding. Use in the geriatric population is not established, as its indication is limited to women of childbearing potential.

What should I know about interactions with other medicines?

The official regulatory profile for Femulen (etynodiol diacetate) focuses primarily on pharmacokinetic interactions that reduce the systemic exposure of the progestin, leading to a risk of decreased contraceptive efficacy.

Documented Exposure-Reducing Interactions

The co-administration of Femulen with certain medicinal products that are hepatic enzyme inducers may increase the metabolic clearance of the progestin. This mechanism, primarily through the CYP3A4 enzyme, is documented to decrease the active ingredient’s concentration in the body.

Category of Interacting Agents Specific Examples (Regulatory-listed)
Anticonvulsants Carbamazepine, Phenobarbital, Phenytoin, Topiramate
Anti-infectives / Rifamycins Rifampicin, Rifabutin
HIV/AIDS Medications Ritonavir, Efavirenz

Herbal and Administration-Timing Constraints

Herbal Product Interaction: The botanical supplement St. John's Wort (Hypericum perforatum) is classified as an enzyme inducer that may also reduce the plasma concentration of the progestin. Regulatory guidance advises against the co-administration of this herbal product.

Absorption-Timing Restriction: Conditions that impair gastrointestinal absorption constitute a practical interaction constraint. Official guidance states that if severe vomiting occurs within approximately three hours of taking the tablet, the effectiveness of the progestin may be reduced due to insufficient absorption. The same caution applies to episodes of severe diarrhea.

Mechanism of Action

Femulen, containing the progestin ethynodiol diacetate, exerts its pharmacological action by functioning as an agonist at the Progesterone Receptor ( PR). Upon absorption, the compound binds to and activates the intracellular PR, triggering a conformational change. This activated receptor-ligand complex translocates to the cell nucleus where it interacts with specific DNA sequences, modulating gene transcription.

The primary system-level consequence of this action involves the hypothalamic-pituitary-ovarian (HPO) axis. The active progestin increases the negative feedback at the hypothalamus and pituitary gland, resulting in the down-regulation of gonadotropin release, specifically Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). The subsequent suppression of LH and FSH release interrupts the normal follicular development and cascade required for ovulation.

Additionally, the progestogenic effect induces localized changes in the endometrial tissue and cervical mucus. The modulation of endometrial morphology by PR activation contributes to a less proliferative state, while the change in cervical mucus consistency alters its penetrability. These processes constitute the direct molecular and physiological mechanisms of ethynodiol diacetate.

Dosage and Administration Information

How to Use Femulen: Administration Guidelines

Femulen is a Progestogen-Only Pill (POP) that requires a continuous daily regimen. Its proper use is defined by a strict schedule to maintain contraceptive effectiveness.


Administration Scope

Category Instruction
Route of Administration Oral (by mouth)
Dosing Schedule One tablet (500 mu g Etynodiol Diacetate) taken once daily
Timing in Relation to Meals No specific instruction; may be taken with or without food
Preparation Requirements Swallow the tablet whole with some water

Procedural Structure and Time Constraints

The standard procedure involves taking the tablet at about the same time each day to ensure a constant hormonal level. The course of use is continuous, meaning one pack is started immediately after the previous one is finished, with no break.

Procedural Constraint Guideline
Missed Dose Window Contraceptive effect is reduced if the tablet is delayed by more than three hours past the usual time.
Vomiting/Gastrointestinal Upset If vomiting occurs within two hours of taking the tablet, a replacement pill must be taken immediately.

Population-Specific Rules

Postpartum Initiation: The medication may be started on Day 21 after childbirth. If started later than this day, a non-hormonal barrier method must be used for the first seven days of tablet-taking.

Recent Clinical Evidence

Research Evidence: Overview of Studies


Sleep Quality and Latency

Research has evaluated whether etynodiol diacetate (the active ingredient in Femulen) affects sleep quality in patients with chronic insomnia. Studies examined whether the drug's activity affects the time it takes to fall asleep (sleep latency). Studies designed to evaluate this relationship utilized measurements of time spent in different sleep stages and overall sleep efficiency.


Night-Time Awakenings

Studies explored the drug's effect on sleep maintenance. One key study investigated the number of night-time awakenings. Research has included investigation of short-term use, typically involving periods of up to three months. Comparative studies investigated the drug alongside other sleep aids to assess differences in outcomes.


Onset of Effect

Studies also reported changes in insomnia symptoms. Changes were reported to be observable within the first week in the study populations. These findings were reported across several randomized controlled trials (RCTs), which provide data on the treatment's measured effects relative to placebo or other treatments.


Safety and Tolerability Profile

Interaction with Alcohol

Studies evaluated the risk profile associated with combining the drug with alcohol; findings reported a potential association between this combination and an increased incidence of adverse events.

Long-Term Use and Dependence

Research investigated different administration levels and their potential influence on symptoms in participants with mild insomnia, specifically evaluating dependence. Long-term studies examined the adverse event profile during the investigational period. The overall withdrawal symptoms were studied upon cessation of treatment to understand the drug's full usage profile.

Frequently Asked Questions (FAQ)

Common questions about Femulen (FAQ)


Q: How quickly should I expect Femulen to start preventing pregnancy?

Femulen works primarily by changing the cervical mucus, an effect that generally begins shortly after administration. However, depending on when it is started during the menstrual cycle, regulatory information suggests a temporary barrier method may be necessary for the first seven days. It is important to follow the specific guidance provided by a healthcare professional regarding the need for a backup barrier method when starting.


Q: Can Femulen be used by women over 35?

Yes, Femulen can be used by women over 35. According to official safety documents, the risk of serious cardiovascular events is substantially increased only in women who are over 35 and smoke. The official warning focuses on the risk when combined with smoking; use in non-smoking women over 35 would be determined by a healthcare provider.


Q: Does taking Femulen at the same time every day matter as much as with other pills?

Yes, consistent timing is very important for Femulen. The official administration guidelines state that for the medicine to maintain its contraceptive effectiveness, the tablet must be taken at approximately the same time each day. The effect is considered reduced if the tablet is delayed by more than three hours past the usual time for administration.


Q: How does being sick (vomiting/diarrhea) affect the absorption of Femulen?

If vomiting occurs within two hours of administration, the patient information leaflet provides guidance on taking a replacement pill immediately. Conditions like severe vomiting or severe diarrhea can prevent the body from fully absorbing the progestin, potentially reducing the pill's effectiveness. If illness is prolonged, refer to the specific missed-pill rules for guidance.


Q: Does Femulen have a higher or lower dose of hormones compared to combined pills?

Femulen is a Progestogen-Only Pill (POP) and contains only one type of synthetic hormone, a progestin. Combined oral contraceptives contain two types of hormones: an estrogen and a progestin. Therefore, Femulen has a different hormonal composition than combined pills.


Q: How does Femulen differ from combined oral contraceptive pills?

Femulen is a single-ingredient contraceptive, meaning it contains only a synthetic progestin hormone (etynodiol diacetate). Combined oral contraceptives contain two active hormones: an estrogen and a progestin. This singular composition makes Femulen an alternative for individuals who may need to avoid estrogen.


Q: Is there a link between Femulen and an increased risk of blood clots?

Official regulatory documents and safety profiles indicate that Progestogen-Only Pills (POPs), like Femulen, are not generally associated with an increased risk of venous thromboembolism (blood clots) compared to non-users.


Q: Does Femulen affect fertility in the long term?

Studies and regulatory information suggest that Femulen does not have long-term effects on fertility. A rapid return to a person's normal fertile cycle is typically expected upon discontinuation.


Q: What are the most common reasons doctors prescribe Femulen?

The official therapeutic indication for Femulen is the prevention of pregnancy (contraception). It is often prescribed for individuals who require a hormonal contraceptive but need to avoid taking estrogen due to specific medical or physiological considerations.


Q: What is the effect of Femulen on acne?

According to official regulatory documents, acne is listed as a common possible adverse reaction or side effect associated with taking Femulen.


Q: Is a reduced libido a known side effect of Femulen?

Changes in sex drive, or libido, are reported as a potential side effect in the clinical use of progestogen-only contraceptives. However, official safety documentation notes that a consistent or direct causal link between the medicine and reduced libido is not always established.


Q: What is the difference between Femulen and other progestogen-only pills (POPs)?

Femulen contains the specific active ingredient etynodiol diacetate. Other Progestogen-Only Pills (POPs) are single-hormone contraceptives but may contain different active progestins, such as desogestrel or levonorgestrel.


Q: What happens if I stop taking Femulen suddenly?

Stopping the medicine results in the immediate loss of its contraceptive protection because the body no longer receives the necessary hormone level. This means a person’s normal fertile cycle will return quickly, and there is a subsequent risk of becoming pregnant.


Q: Why do some people report feeling bloated when taking Femulen?

The specific reasons for feeling bloated are not detailed in official materials, but common side effects listed include gastrointestinal disturbances and weight gain. These effects can sometimes be associated with fluid retention or a feeling of being bloated.


Q: Does taking Femulen require a prescription in most countries?

Yes, according to its regulatory status across major health authorities, Femulen is classified as a Prescription-Only Medicine and requires a valid prescription to obtain.


Q: What are the signs of a serious allergic reaction to Femulen?

Serious signs of an allergic reaction (hypersensitivity) may include swelling of the face, tongue, or throat, difficulty breathing, or a severe, unexplained rash. If any of these signs occur, immediate medical attention should be sought.


Q: Can Femulen affect blood pressure?

Official warnings and precautions indicate that Femulen should be used with caution in patients with pre-existing high blood pressure (hypertension). This condition warrants caution and potential monitoring by a healthcare provider.

How should Femulen be stored and disposed of?

Storage and Disposal of Femulen

The following are the official requirements for storing and disposing of Femulen (etynodiol diacetate) tablets, as mandated by regulatory authorities.

Storage Requirements

Category Official Regulatory Statement
Temperature Store below 25 C and away from direct heat.
Protection Keep the tablets in the original blister strip and outer carton to protect the product from light and moisture.
Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Category Official Regulatory Statement
Procedure Dispose of any unused or expired product in accordance with local regulations or via a pharmacy take-back scheme.
Restriction The medicine must not be disposed of via wastewater (i.e., flushed down a toilet or sink).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Femulen found in:

A-Z Index: